Modera Wealth Management LLC Cuts Stock Holdings in Novo Nordisk A/S $NVO

Modera Wealth Management LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 4.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 342,482 shares of the company’s stock after selling 16,605 shares during the period. Modera Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $17,426,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Martin Capital Partners LLC boosted its position in Novo Nordisk A/S by 53.8% during the third quarter. Martin Capital Partners LLC now owns 117,577 shares of the company’s stock valued at $6,524,000 after buying an additional 41,129 shares during the period. Smith Chas P & Associates PA Cpas boosted its position in Novo Nordisk A/S by 105.3% during the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company’s stock valued at $22,497,000 after buying an additional 207,959 shares during the period. Clifford Swan Investment Counsel LLC boosted its position in Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company’s stock valued at $17,267,000 after buying an additional 37,453 shares during the period. Markel Group Inc. boosted its position in Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company’s stock valued at $131,436,000 after buying an additional 110,061 shares during the period. Finally, Cantor Fitzgerald Investment Advisors L.P. purchased a new stake in Novo Nordisk A/S during the third quarter valued at about $1,294,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently commented on NVO. Jefferies Financial Group raised shares of Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They set a “peer perform” rating for the company. HSBC reaffirmed a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Citigroup began coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 27th. They set a “neutral” rating for the company. Finally, Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. Four analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $65.56.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Early reports show the newly launched Wegovy oral pill is expanding the obesity-treatment market by attracting patients who hadn’t used injectable GLP‑1s, suggesting incremental demand rather than a simple channel shift — a positive signal for longer-term sales growth. Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
• Positive Sentiment: Novo initiated a share repurchase programme (part of up to DKK 15 billion over 12 months), which supports the stock and signals capital-return intent — though the size is modest relative to market cap. Novo Nordisk A/S – Share repurchase programme
• Neutral Sentiment: A partner (Hims & Hers) is positioning to capture weight‑loss demand tied to GLP‑1s, which could broaden distribution channels for products tied to Novo’s ecosystem, but the direct financial impact on Novo is indirect and currently unclear. Hims & Hers (HIMS) Taps Into $200-Billion Weight Loss Market, Soars 6%
• Neutral Sentiment: Management commentary and company messaging continue to assert the weight‑loss market is still early and large, supporting a long-term growth narrative but offering limited near-term clarity on margins and market share. Novo Says Weight-Loss Boom Is Just Beginning
• Negative Sentiment: An analyst downgrade to “Sell” flagged pipeline and competitive risks for Novo’s GLP‑1 franchise, raising concerns about future growth and amplifying selling pressure. Novo Nordisk: Downgrading To ‘Sell’ As GLP-1 Pipeline Faces Many Risks
• Negative Sentiment: Analyst and media scrutiny questions whether Novo’s recent buyback size and pace reflect confidence or caution given shrinking market share to Eli Lilly and sustained share-price weakness. That narrative is weighing on sentiment. Nuclear, Pharma & Travel Buybacks: Confident or Cautious Signals?

Novo Nordisk A/S Price Performance

NVO stock opened at $36.66 on Tuesday. Novo Nordisk A/S has a 1 year low of $35.12 and a 1 year high of $81.44. The company has a market cap of $163.70 billion, a P/E ratio of 10.57, a PEG ratio of 8.75 and a beta of 0.73. The firm has a 50-day moving average of $42.88 and a 200 day moving average of $49.56. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. On average, sell-side analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio is presently 50.43%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.